G-Therapeutics, Vincent Delattre

G-Therapeutics, Vincent Delattre

by Vincent Delattre

Applied Sciences & Engineering Economics & Finance KJBusiness and ManagementKJHEntrepreneurship
🎙 Vincent Delattre 👥 6K 📅 September 30, 2015 ⏱ 11 min 👁 493 📄 expert opinion 🧭 2026-08-18
Available in: English (current) Français

Keywords

spinal cord injuryelectrical stimulationrobotic trainingimplantable stimulatorrehabilitation

Summary

Vincent Delattre, co-founder of G-Therapeutics, presents his company’s mission to develop a therapy for spinal cord injury (SCI) patients. The approach combines electrical stimulation of the spinal cord with robot-assisted training to promote neural rewiring and recovery of locomotion. The company aims to translate this from animal models to human application, developing two products: an implantable spinal cord stimulator and a robotic rehabilitation platform. The team includes academics from EPFL and a neurosurgeon, with plans to raise 40 million Swiss francs. They have already conducted a proof-of-concept at Lausanne University Hospital. The pitch includes Q&A addressing surgical feasibility, business execution, scaling, and revenue models. The therapy has shown success in fully paralyzed animals, but human testing is still in early stages. The company plans to achieve CE marking by 2020 and FDA approval for testing in the US. The presentation highlights the potential to improve autonomy and quality of life for SCI patients.

153 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information lies in the presentation of a novel therapeutic approach for spinal cord injury, combining electrical stimulation and robotic training. The argumentation is based on the team’s academic background and promising animal studies, but lacks detailed scientific evidence and clinical data. The pitch is persuasive but relies on the potential of the technology rather than proven results. The business model is outlined, but the feasibility of scaling and regulatory approval is not deeply analyzed.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is moderate: the approach is grounded in established research, but the presentation does not cite specific studies or sources. The quality of sources is limited to the team’s own work and general knowledge. The title accurately reflects the content, which is a startup pitch. The Q&A provides some insight into challenges, but the overall evidence is anecdotal.

153 words

Title / Content Match

The title accurately reflects the content: a pitch by Vincent Delattre for G-Therapeutics.

Quality & Reliability

6/10

The pitch presents a plausible scientific approach based on prior animal studies, but lacks detailed data, peer-reviewed references, and independent validation. The claims are promising but not yet proven in humans.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

Concurring Sources

Contribution & Novelties

The pitch presents a novel combination of electrical stimulation and robotic training for spinal cord injury rehabilitation, with a clear path to clinical translation. The approach has been tested in animals and is moving to human trials.

Pour aller plus loin :

  • Spinal cord injury — Overview of the condition.
  • Neuroprosthetics — Field of implantable devices for neural function.
  • Epidural electrical stimulation — Technique used in the approach.

68 words

Radar Profile

The radar profile shows moderate scores across all dimensions, with a slight peak in technical level, reflecting the specialized nature of the pitch. The overall balance suggests a competent but not exceptional presentation.

Reliability 5/10